131 related articles for article (PubMed ID: 17371466)
1. Macroprolactinomas and epilepsy.
Deepak D; Daousi C; Javadpour M; MacFarlane IA
Clin Endocrinol (Oxf); 2007 Apr; 66(4):503-7. PubMed ID: 17371466
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
4. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
5. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
6. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
7. Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon?
Nadesapillai S; Balcere I; Kaye AH; Tress BM; Colman PG
J Clin Neurosci; 2004 Nov; 11(8):825-8. PubMed ID: 15519856
[TBL] [Abstract][Full Text] [Related]
8. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinaemia.
Prabhakar VK; Davis JR
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
[TBL] [Abstract][Full Text] [Related]
10. Meningitis as a presentation of macroprolactinoma.
Honegger J; Psaras T; Petrick M; Reincke M
Exp Clin Endocrinol Diabetes; 2009 Jul; 117(7):361-4. PubMed ID: 19591087
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome.
Iglesias P; Bernal C; Villabona C; Castro JC; Arrieta F; Díez JJ
Clin Endocrinol (Oxf); 2012 Aug; 77(2):281-7. PubMed ID: 22288612
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous cerebrospinal fluid rhinorrhea in untreated macroprolactinoma--an indication for primary surgical therapy.
Honegger JB; Psaras T; Petrick M; Beuschlein F; Reincke M
Zentralbl Neurochir; 2006 Aug; 67(3):149-54. PubMed ID: 16958013
[TBL] [Abstract][Full Text] [Related]
13. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
14. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.
Greenman Y; Tordjman K; Osher E; Veshchev I; Shenkerman G; Reider-Groswasser II; Segev Y; Ouaknine G; Stern N
Clin Endocrinol (Oxf); 2005 Jul; 63(1):39-44. PubMed ID: 15963059
[TBL] [Abstract][Full Text] [Related]
15. Macroprolactinomas as cause of delayed puberty. A report of two cases and effects of medical therapy.
Minniti G; Jaffrain-Rea ML; Ferretti E; Gulino A; Tamburrano G
Minerva Endocrinol; 1996 Jun; 21(2):67-71. PubMed ID: 8968149
[TBL] [Abstract][Full Text] [Related]
16. Outcome following surgery for temporal lobe epilepsy with hippocampal involvement in preadolescent children: emphasis on mesial temporal sclerosis.
Smyth MD; Limbrick DD; Ojemann JG; Zempel J; Robinson S; O'Brien DF; Saneto RP; Goyal M; Appleton RE; Mangano FT; Park TS
J Neurosurg; 2007 Mar; 106(3 Suppl):205-10. PubMed ID: 17465386
[TBL] [Abstract][Full Text] [Related]
17. [The effect of oxcarbamazepine on the clinical effectiveness of dopamine agonists in the treatment of prolactinoma].
Krysiak R; Kedzia A; Okopień B
Wiad Lek; 2011; 64(4):279-82. PubMed ID: 22533152
[TBL] [Abstract][Full Text] [Related]
18. Oligoastrocytoma presenting with intractable epilepsy.
Hiremath GK; Bingaman WE; Prayson RA; Nair D
Epileptic Disord; 2007 Sep; 9(3):315-22. PubMed ID: 17884756
[TBL] [Abstract][Full Text] [Related]
19. A combined case of macroprolactinoma, growth hormone excess and Graves' disease.
Hussein Z; Tress B; Colman PG
Med J Malaysia; 2005 Jun; 60(2):232-6. PubMed ID: 16114168
[TBL] [Abstract][Full Text] [Related]
20. Outcome predictors for surgical treatment of temporal lobe epilepsy with hippocampal sclerosis.
Aull-Watschinger S; Pataraia E; Czech T; Baumgartner C
Epilepsia; 2008 Aug; 49(8):1308-16. PubMed ID: 18754943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
